Nguyen P L, Swanson P E, Jaszcz W, Aeppli D M, Zhang G, Singleton T P, Ward S, Dykoski D, Harvey J, Niehans G A
Department of Laboratory Medicine and Pathology, School of Public Health, University of Minnesota, Minneapolis.
Am J Clin Pathol. 1994 Feb;101(2):166-76. doi: 10.1093/ajcp/101.2.166.
Epidermal growth factor receptor (EGFR) immunoreactivity was evaluated in 85 cases of invasive transitional cell carcinoma of the bladder. The impact of EGFR staining on patient survival was compared with tumor stage, histologic grade, immunoreactivity for c-erb B-2 and proliferating cell nuclear antigen, flow cytometrically determined S-phase fraction and DNA ploidy, abnormal expression of blood-group-related antigens, and patient blood type. Using a new monoclonal anti-EGFR antibody reactive in formalin-fixed tissue, the authors found a significant correlation between EGFR expression and high tumor stage, and between EGFR expression and poor patient outcome. However, EGFR expression as a predictor of prognosis was not independent of stage. An intriguing association between patient blood type and patient survival was noted. Other indices did not predict patient outcome after data were adjusted for stage.
对85例膀胱浸润性移行细胞癌病例评估了表皮生长因子受体（EGFR）免疫反应性。将EGFR染色对患者生存的影响与肿瘤分期、组织学分级、c-erb B-2和增殖细胞核抗原的免疫反应性、流式细胞术测定的S期分数和DNA倍性、血型相关抗原的异常表达以及患者血型进行了比较。使用一种在福尔马林固定组织中有反应性的新型抗EGFR单克隆抗体，作者发现EGFR表达与高肿瘤分期之间以及EGFR表达与患者不良预后之间存在显著相关性。然而，EGFR表达作为预后的预测指标并非独立于分期。注意到患者血型与患者生存之间存在有趣的关联。在对分期进行数据调整后，其他指标不能预测患者预后。
